Biologica Technologies, developers of ProteiOS® growth factor and OsseoGEN® cellular bone matrix, announced early topline results from a retrospective, multicenter study evaluating the safety and effectiveness of ProteiOS in foot and ankle fusion. Thus far, study results show fusion rates that are higher than or comparable to those in other published studies of any other bone graft material, including but not limited to autograft, cellular bone matrices and PDGF-BB.
Biologica Technologies ProteiOS Growth Factor
In this retrospective, multicenter study, ProteiOS has thus far been evaluated in 79 patients undergoing 121 foot and ankle fusion procedures with the primary endpoint deemed successful fusion based on high-resolution CT scans and radiographs assessed by a blinded, independent radiologist. Based on radiographic evaluation, the data demonstrated a fusion rate of 75.2% at six months and 97.1% fusion at 12 months.
ProteiOS has been shown to include more than 600 naturally occurring growth factors including, but not limited to BMP-2, PDGF, TGF-β1 and VEGF. Its lyophilized format supports the use of virtually any scaffold during implantation.
“These study results mirror the anecdotal evidence we have been hearing about ProteiOS from surgeons and sales representatives in the field,” said Jason Mattiello, Vice President of Sales. “It is exciting to have this data and also to be at our first in-person conference in over a year!”
Biologica Technologies, developers of ProteiOS® growth factor and OsseoGEN® cellular bone matrix, announced early topline results from a retrospective, multicenter study evaluating the safety and effectiveness of ProteiOS in foot and ankle fusion. Thus far, study results show fusion rates that are higher than or comparable to those in other...
Biologica Technologies, developers of ProteiOS® growth factor and OsseoGEN® cellular bone matrix, announced early topline results from a retrospective, multicenter study evaluating the safety and effectiveness of ProteiOS in foot and ankle fusion. Thus far, study results show fusion rates that are higher than or comparable to those in other published studies of any other bone graft material, including but not limited to autograft, cellular bone matrices and PDGF-BB.
Biologica Technologies ProteiOS Growth Factor
In this retrospective, multicenter study, ProteiOS has thus far been evaluated in 79 patients undergoing 121 foot and ankle fusion procedures with the primary endpoint deemed successful fusion based on high-resolution CT scans and radiographs assessed by a blinded, independent radiologist. Based on radiographic evaluation, the data demonstrated a fusion rate of 75.2% at six months and 97.1% fusion at 12 months.
ProteiOS has been shown to include more than 600 naturally occurring growth factors including, but not limited to BMP-2, PDGF, TGF-β1 and VEGF. Its lyophilized format supports the use of virtually any scaffold during implantation.
“These study results mirror the anecdotal evidence we have been hearing about ProteiOS from surgeons and sales representatives in the field,” said Jason Mattiello, Vice President of Sales. “It is exciting to have this data and also to be at our first in-person conference in over a year!”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
